Fatma Yeşim PARMAN, Devrim TARAKÇI, Elâ TARAKÇI, Hacer DURMUŞ TEKÇE, Feza DEYMEER, Zehra Piraye OFLAZER, Arzu Razak ÖZDİNÇLER, Gülcan AKSOY, Sezan MERGEN KILIÇ, Hakan BEŞER, Çiğdem BEŞER, Habibe Serap İNAL

Turkish version of the Motor Function Measure Scale (MFM-32) forneuromuscular diseases: a cross-cultural adaptation, reliability, and validity study

Background/aim: The Motor Function Measure (MFM-32) is a classification system for ambulant and nonambulant patients with neuromuscular diseases (NMDs). We aimed to translate it into Turkish, culturally adapt it, and test its reliability and validity for Turkish patients with NMDs. Materials and methods: The translation of the 32 items assessing three functional areas: standing position and transfers (D1: 13), axial/proximal (D2: 12), and distal (D3: 7) motor functions was performed according to the established guidelines for cross-cultural adaptation. Totally 51 patients (12.56 ± 8.84 years; F/M 12/39) were tested. Vignos and Brooke scores for the lower and upper extremities, respectively, were used for the validity of the MFM-32-TR items, which were rated on a 4-point Likert scale. Results: The agreement coefficients for interrater reliability were excellent (0.72 0.93) for 10 items, good (0.58 0.77) for 16 items, and moderate (0.42 0.56) for 6 items of the MFM-32-TR. The intertester reliability varied from good to excellent and the intraclass correlation coefficient was 0.76 0.93. The MFM-32-TR positively correlated with Vignos and Brooke scores with coefficients 0.47 to 0.75, indicating concurrent validity. Conclusion: The MFM-32-TR is a reliable and valid outcome measure for the assessment of motor function of people with NMDs in our sociocultural context.

PDF

___

1. Campbell KP. Three muscular dystrophies: loss of cytoskeletonextracellular matrix linkage. Cell 1995; 8: 675-679.
2. Rossi R, Alexander MCS. Pediatric Rehabilitation. In: Physical Medicine and Rehabilitation Board Review. New York, NY, USA: Demos Medical Publishing; 2004; pp. 713-808.
3. OHagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, Rilay S, Sanborn E, Irvine C, Matrens WB, Annis C et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscular Disord 2007; 17: 693-697.
4. Glanzman AM, OHagen JM, McDermott MP, Martens WB, Flickinger J, Riley S, Quigley J, Montes J, Dunaway S, Deng L et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol 2011; 26: 1499-1507.
5. Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, Van den Hauwe M, Mercuri E. Hammersmith functional motor scale and motor function measure-20 in non-ambulant SMA patients. Neuromuscular Disord 2014; 24: 347-352.
6. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Muntoni F. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012; 17: 101-109.
7. Mazzone ES, Messina S, Vasco G, Main M, Eagle M, DAmico A, Doglio L, Politano L, Cavallaro F, Frosini S et al. Reliability of the North Star Ambulatory Assessment in a multicenter setting. Neuromuscular Disord 2009; 19: 458-461.
8. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981; 4: 186-197.
9. Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood. JAMA-J Am Med Assoc 1963; 184: 89-96.
10. Bérard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscular Disord 2005; 15: 463- 470.
11. Vuillerot C, Girardot F, Payan C., Fermanian J, Iwaz J, De lattre C, Berard C. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol 2010; 52: 60-65.
12. Iwabe C, Miranda-Pfeilsticker BH, Nucci A. Motor function measure: portuguese version and reliability analysis. Rev Bras Fisioter 2008; 12: 417-424.
13. Bérard C, Vuillerot C, Girardot F, Hamroun D, Payan C. La Mesure de Fonction Motrice, une échelle validée pour les MNM. Les cahiers de Myologie 2010; 2: 26-34.
14. Vuillerot C, Meilleur KG, Jain M, Waite M, Wu T, Linton M, Bönnemann CG. English cross-cultural translation and validation of the neuromuscular score: a system for motor function classification in patients with neuromuscular diseases. Arch Phys Med Rehabil 2014; 95: 2064-2070.
15. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000; 25: 3186-3191.
16. Gamer M, Lemon J, Fellows I, Singh P. (2012). irr: Various Coefficients of Interrater Reliability and Agreement. R package version 0.84. Internet resource: http://CRAN.R-project.org/ package= irr. Verified April, 10, 2013.M.
17. Gwet KL. Handbook of inter-rater reliability: the definitive guide to measuring the extent of agreement among raters. Advanced Analytics, LLC, 2014.
18. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chirop Med 2016; 15: 155-163.
19. Vuillerot C, Rippert P, Roche S, Bérard C, Margirier F, de Lattre C, Le groupe détude NM Score. Development and validation of a motor function classification in patients with neuromuscular disease: the NM-Score. Ann Phys Rehabil Med 2013; 56: 673- 686.